DNA methylation profiles for breast cancer subtype classifications: A translational study from microarray to methylation-specific PCR (MSP)
Narra J · 2025
DOI: 10.52225/narra.v5i1.1364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Narra J, 2025. Verfasst von Sonar S Panigoro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. Hauptthemen laut MEDLINE: DNA Methylation, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Breast cancer subtypes can be categorized based on their gene expression profiles using immunohistochemistry into Luminal A, Luminal B, human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer (TNBC) subtypes. However, immunohistochemistry has certain limitations that can lead to misclassification. DNA methylation is an epigenetic modification, and changes in the promoter region can alter gene expression and the quantity of functional protein synthesized, disrupting gene function. The aim of this study was to identify DNA methylation biomarkers for subtype classification in breast cancer using microarray and methylation-specific polymerase chain reaction (MSP) methods. DNA samples were extracted, subjected to bisulfite conversion and then used for both the microarray and MSP methods. This study successfully identified differentially methylated CpGs (DMCs) as biomarker for each subtype classification of breast cancer: Luminal A (hypermethylation of ADAMTSL2 gene; cg14397888), Luminal B (hypomethylation of ADAMTSL2 gene; cg14397888), HER2+ (hypermethylation of PTPRN2 gene; cg25910261), and TNBC (hypomethylation of LCLAT1 gene; cg15652532). The DMC biomarker found for the HER2+ subtype, hypermethylation in the PTPRN2 gene (cg25910261), has the potential to be used by healthcare providers to identify HER2+ patients and provide the HER2-targeted therapy to improve the patient’s survival. In addition, our developed MSP method could produce an effective diagnostic tool for classifying the Luminal A and Luminal B subtypes, with accuracies of 75% and 76%, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
- Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
- Department of Medical Chemistry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
- Bioinformatics Core Facilities - IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
- Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Zitieren
APA
Panigoro, S. S., Paramita, R. I., Wanandi, S. I., Fadilah, F., Wibisana, I. G., & Sutandyo, N. (2025). DNA methylation profiles for breast cancer subtype classifications: A translational study from microarray to methylation-specific PCR (MSP). Narra J. https://doi.org/10.52225/narra.v5i1.1364
Vancouver
Panigoro SS, Paramita RI, Wanandi SI, Fadilah F, Wibisana IG, Sutandyo N. DNA methylation profiles for breast cancer subtype classifications: A translational study from microarray to methylation-specific PCR (MSP). Narra J. 2025. doi:10.52225/narra.v5i1.1364
BibTeX
@article{Panigoro2025,
author = {Panigoro, Sonar S and Paramita, Rafika I and Wanandi, Septelia I and Fadilah, Fadilah and Wibisana, I Gng and Sutandyo, Noorwati},
title = {DNA methylation profiles for breast cancer subtype classifications: A translational study from microarray to methylation-specific PCR (MSP)},
journal = {Narra J},
year = {2025},
doi = {10.52225/narra.v5i1.1364}
}
EUVIMED